Advertisement

rMark Bio Leverages Cognitive Computing to Build SaaS Platform for Pharmaceutical Companies

By on

by Angela Guess

A recent press release reports, “rMark Bio, headquartered in Chicago, Illinois, is bridging the gap between pharmaceutical companies and researchers through their deep learning analytics platform. rMark Bio is a business intelligence Software as a Service (SaaS) that uses cognitive computing to derive strategic recommendations and insights after mining global health data, clinical trials, and academic research along with internal company data.”

The release goes on, “Collaborative partnerships between pharmaceutical companies and academia are essential for identifying new drug targets, consulting on drug markets, and sales and marketing efforts. However, the approaches by which companies identify partners are inefficient, resulting in wasted money, time, and opportunity. ‘This problem is compounded by the rising number of clinicians and academic researchers and by the increasing volume and complexity of the data that they produce,’ says Dr. Lev Becker Co-founder and Assistant Professor at the University of Chicago. In response to these challenges, rMark Bio developed a deep learning analytics platform that increases the efficiency by which pharmaceutical companies identify, partner, and manage partnerships with clinical and academic scientists.”

The release adds, “rMark Bio’s Collaboration Recommendation Engine (CoRE) platform is built on top of the cognitive computing power of IBM Watson. CoRE starts by capturing and analyzing daily information about clinical practitioners and academic scientists and their research. Next, CoRE analyzes a company’s team, current partnerships, internal research data, and corporate goals. Finally, by aligning the analysis of external health data and a company’s internal data, CoRE delivers prioritized partnership recommendations, engagement strategies, and insights for therapeutic areas of interest. As the needs of a company change, CoRE adjusts its recommendations by intelligently tailoring new insights that align with the shifting priorities.”

Read more at PR Newswire.

Photo credit: rMark Bio

Leave a Reply